Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation.
Stefan D AnkerTim FriedeRalph-Stephan von BardelebenJaved ButlerMuhammad-Shahzeb KhanMonika DiekJutta HeinrichMartin GeyerMarius PlaczekRoberto FerrariWilliam T AbrahamOttavio AlfieriAngelo AuricchioAntoni Bayes-GenisJohn G F ClelandGerasimos FilippatosFinn GustafssonWilhelm HaverkampMalte KelmKarl-Heinz KuckUlf LandmesserAldo Pietro MaggioniMarco MetraVlasis NiniosMark C PetrieTienush RassafFrank RuschitzkaUlrich SchäferP Christian SchulzeKonstantinos SpargiasAlec VahanianJose Luis ZamoranoAndreas ZeiherMahir KarakasFriedrich KoehlerMitja LainscakAlper ÖnerNikolaos MezilisEfstratios K TheofilogiannakosIlias NiniosMichael ChrissoherisPanagiota KourkoveliKonstantinos PapadopoulosGrzegorz SmolkaWojciech WojakowskiKrzysztof ReczuchFausto J PintoŁukasz WiewiórkaZbigniew KalarusMarianna AdamoEvelyn Santiago-VacasTobias F RufMichael GrossJoern TongersGerd HasenfussWolfgang SchillingerPiotr Ponikowskinull nullPublished in: The New England journal of medicine (2024)
Among patients with heart failure with moderate to severe functional mitral regurgitation who received medical therapy, the addition of transcatheter mitral-valve repair led to a lower rate of first or recurrent hospitalization for heart failure or cardiovascular death and a lower rate of first or recurrent hospitalization for heart failure at 24 months and better health status at 12 months than medical therapy alone. (Funded by Abbott Laboratories; RESHAPE-HF2 ClinicalTrials.gov number, NCT02444338.).